Overview

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
MedImmune LLC
Treatments:
Benralizumab